Back

Effects of sacubitril-valsartan on clinical, echocardiographic and polygraphic parameters in patients affected by heart failure with reduced ejection fraction and sleep apnea

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Neprilysin inhibition: news and nuggets Heart Failure with Reduced Ejection Fraction (HFrEF) ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Giuseppe Armentaro

University Hospital Renato Dulbecco, Catanzaro (Italy)

5 More presentations in this session

Presentation thumbnail
Sacubitril/valsartan compared to ramipril in high risk post myocardial infarction patients stratified according use of mineralocorticoid receptor antagonists: Insight from PARADISE MI trial
Professor M. Schou (Gentofte, DK)
Abstract Slides Video
Presentation thumbnail
ARNI effects in HFrEF. Risk reduction beyond LVEF
Doctor A. Boehmer (Wiesbaden, DE)
Abstract Slides Video
Presentation thumbnail
Prevalent and incident anaemia in PARADIGM-HF and effect of sacubitril/valsartan
Doctor J. Curtain (Dublin, IE)
Abstract Slides Video
Presentation thumbnail
Effects of angiotensin receptor-neprilysin inhibitors (ARNIs) on the glucose and fat metabolism biomarkers leptin and fructosamin
Doctor B. Ohnewein (Salzburg, AT)
Abstract Slides Video
Presentation thumbnail
Effect of sacubitril/valsartan on endothelial dysfunction and arterial stiffness in patients with chronic heart failure
Doctor V. Cassano (Catanzaro, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Neprilysin inhibition: news and nuggets
Video

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Effect of sglt2-inhibitors on polygraphic parameters in elderly patients affected by heart failure and sleep apnea
thumbnail
Congress Presentation
Impact of sleep apnea syndrome on heart failure
thumbnail
Congress Presentation
Right ventricular echocardiographic parameters predicting the severity of sleep apnea syndrome in patients with heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources